| Document And Entity Information | Aug. 12, 2021 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Aug. 12, 2021 |
| Entity Registrant Name | Lyell Immunopharma, Inc. |
| Entity Central Index Key | 0001806952 |
| Entity Emerging Growth Company | true |
| Entity File Number | 001-40502 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 83-3006753 |
| Entity Address, Address Line One | 400 EAST JAMIE COURT, SUITE 301 |
| Entity Address, City or Town | SOUTH SAN FRANCISCO |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94080 |
| City Area Code | 650 |
| Local Phone Number | 695-0677 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Ex Transition Period | false |
| Title of 12(b) Security | Common Stock, $0.0001 par value per share |
| Trading Symbol | LYEL |
| Security Exchange Name | NASDAQ |
